Gene therapy has remained a constant prospect in the sphere of hemophilia treatment. For over two decades and the question remained: Is this just a dream, or could it one day become a reality?
Hemophilia gene therapy has finally been approved.
David Page talks to hemophilia specialists that will dive deep into understanding how the treatment works, its significance in advancing treatment, and how a one time treatment could change a severe condition to a milder one.Though not a definitive cure, gene therapy for hemophilia has transformed the dream of a cure into a reality for the future.
David and his guests will provide exclusive insights into one of the most significant medical breakthroughs of our era.
In this podcast, Dr. David Lillicrap presents the results of clinical trials in hemophilia A and hemophilia B gene therapy. He describes how high factor VIII and IX levels can rise, how predictable this response is from person to person, and how long the therapy may be effective. Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, and is world renowned for his research in hemophilia gene therapy.
Canadian Hemophilia Society
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.